Moss Gregory S. 4

What Happened

Gregory S. Moss, Evommune's Chief Business & Legal Officer, was granted a derivative award for 115,279 shares on 2026-04-16 (reported on Form 4 filed 2026-04-17). The filing lists the acquisition price as $0.00 and classifies the transaction as an award/grant (code A). This is a grant of equity-linked securities (reported as a derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-17 (filed timely).
• Securities: 115,279 shares (derivative award) at $0.00 reported; total reported cash value = $0.
• Shares owned after transaction: Not disclosed in the provided data.
• Footnote on vesting (F1): One fourth (1/4) vests on the first anniversary of the grant date; the remaining shares vest in 36 equal monthly installments thereafter, subject to continuous service.
• Transaction type: Award/Grant (A). No sale or exercise occurred; no 10b5-1 or tax-withholding notation provided.

Context

This filing reports a time‑based equity grant to an executive and includes a multi-year vesting schedule. Because it is a derivative award (not an immediate sale or exercise), it does not reflect an immediate change in market share ownership or liquidity. Such grants are common for executive compensation and are intended to align long-term interests; they should be interpreted as future potential equity rather than an instant market transaction.